Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences Inc (NQ: ENVB )

0.3323 -0.0077 (-2.26%)
Streaming Delayed Price Updated: 12:13 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Enveric Biosciences Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders
Via Benzinga
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
Enveric licenses EB-002 to MycoMedica for neuropsychiatric treatment, focusing on EB-003's development with potential milestones up to $62M. 
Via Benzinga
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions
Enveric Biosciences expands its patent portfolio with five new U.S. patents, supporting treatments for depression, anxiety and epilepsy. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?
Enveric Biosciences stock is up on Tuesday with heavy trading of ENVB shares despite a lack of news from the company this morning. 
Via InvestorPlace
Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic
Enveric Biosciences announces positive preclinical results for EB-003, showcasing its potential as a safe and effective treatment for mental health disorders. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options. 
Via Benzinga
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being... 
Via Benzinga
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024
ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is Imunon (IMNN) Stock Up 259% Today?
Imunon stock is up on Tuesday with heavy trading of IMNN shares after posting positive results from a Phase 2 clinical trial. 
Via InvestorPlace
Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
Ekso Bionics stock is down on Tuesday as investors in the company react to its lackluster earnings report for the second quarter of the year. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning! 
Via InvestorPlace
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally
Via Benzinga
New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies
Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024
ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand
Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the... 
Via Benzinga
Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods
The news of the licensee deal comes on the heels of the DEA's move to reschedule marijuana, one source of cannabinoids, as a Schedule III controlled substance. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... 
Via Benzinga
Exposures Glyphosate
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023
ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.